| Primary |
| Drug Use For Unknown Indication |
15.2% |
| Product Used For Unknown Indication |
13.3% |
| Nausea |
11.3% |
| Premedication |
9.4% |
| Prophylaxis Of Nausea And Vomiting |
7.4% |
| Vomiting |
6.6% |
| Breast Cancer |
5.5% |
| Chemotherapy |
3.9% |
| General Anaesthesia |
3.9% |
| Drug Exposure During Pregnancy |
3.5% |
| Antiemetic Supportive Care |
3.1% |
| Hyperemesis Gravidarum |
2.7% |
| Pain |
2.3% |
| Anaesthesia |
2.0% |
| Induction Of Anaesthesia |
2.0% |
| Procedural Nausea |
2.0% |
| Pain Management |
1.6% |
| Prophylaxis |
1.6% |
| Pulmonary Tuberculosis |
1.6% |
| Acute Gastroenteritis |
1.2% |
|
| Vomiting |
19.1% |
| Constipation |
10.3% |
| Tremor |
7.4% |
| Dystonia |
5.9% |
| Rash |
5.9% |
| Erythema |
4.4% |
| Maternal Exposure During Pregnancy |
4.4% |
| Maternal Exposure Timing Unspecified |
4.4% |
| Tachycardia |
4.4% |
| Vision Blurred |
4.4% |
| Foetal Growth Restriction |
2.9% |
| Long Qt Syndrome |
2.9% |
| Menorrhagia |
2.9% |
| Oxygen Saturation Decreased |
2.9% |
| Sinus Tachycardia |
2.9% |
| Somnolence |
2.9% |
| Syncope |
2.9% |
| Urticaria |
2.9% |
| Urticaria Vesiculosa |
2.9% |
| Ventricular Hypokinesia |
2.9% |
|
| Secondary |
| Prophylaxis Of Nausea And Vomiting |
22.2% |
| Drug Use For Unknown Indication |
16.6% |
| Product Used For Unknown Indication |
9.2% |
| Nausea |
7.0% |
| General Anaesthesia |
4.8% |
| Prophylaxis |
4.4% |
| Vomiting |
3.5% |
| Premedication |
3.4% |
| Pain |
3.1% |
| Drug Exposure During Pregnancy |
3.0% |
| Acute Lymphocytic Leukaemia |
2.8% |
| Breast Cancer |
2.8% |
| Lung Neoplasm Malignant |
2.6% |
| Chemotherapy |
2.4% |
| Osteosarcoma |
2.4% |
| Hypotension |
2.3% |
| T-cell Type Acute Leukaemia |
2.0% |
| Bipolar Disorder |
1.9% |
| Foetal Exposure During Pregnancy |
1.9% |
| Bone Sarcoma |
1.7% |
|
| Vomiting |
19.8% |
| Electrocardiogram T Wave Inversion |
10.4% |
| Supraventricular Tachycardia |
10.4% |
| Faecaloma |
7.3% |
| Lymphopenia |
5.2% |
| Hypophagia |
4.2% |
| Myocardial Infarction |
4.2% |
| Nausea |
4.2% |
| Toxic Epidermal Necrolysis |
4.2% |
| Death |
3.1% |
| Liver Injury |
3.1% |
| Peripheral Motor Neuropathy |
3.1% |
| Pupils Unequal |
3.1% |
| Sepsis |
3.1% |
| Tachypnoea |
3.1% |
| Ventricular Fibrillation |
3.1% |
| Bradycardia |
2.1% |
| Dermatitis Exfoliative |
2.1% |
| Drug Ineffective |
2.1% |
| Encephalopathy |
2.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
38.2% |
| Drug Use For Unknown Indication |
11.6% |
| Nausea |
9.0% |
| Pain |
6.2% |
| Non-small Cell Lung Cancer |
4.1% |
| Crohn's Disease |
3.1% |
| Vomiting |
3.1% |
| Prophylaxis |
2.9% |
| Multiple Myeloma |
2.6% |
| Premedication |
2.4% |
| Anxiety |
2.2% |
| Constipation |
2.1% |
| Breast Cancer |
2.0% |
| Hypertension |
2.0% |
| Depression |
1.6% |
| Insomnia |
1.5% |
| Mantle Cell Lymphoma |
1.4% |
| Acute Myeloid Leukaemia |
1.4% |
| Colorectal Cancer Metastatic |
1.3% |
| Colorectal Cancer |
1.1% |
|
| Vomiting |
19.4% |
| Thrombocytopenia |
8.6% |
| Death |
8.3% |
| White Blood Cell Count Decreased |
6.9% |
| Nausea |
5.4% |
| Renal Failure Acute |
4.6% |
| Urinary Tract Infection |
4.6% |
| Febrile Neutropenia |
4.3% |
| Pain |
4.0% |
| Pyrexia |
3.7% |
| Renal Failure |
3.7% |
| Sepsis |
3.7% |
| Weight Increased |
3.4% |
| Dehydration |
3.1% |
| Pulmonary Embolism |
3.1% |
| Rash |
3.1% |
| Multiple Myeloma |
2.6% |
| Pneumonia |
2.6% |
| Tumour Lysis Syndrome |
2.6% |
| Fatigue |
2.3% |
|
| Interacting |
| Hepatosplenic Candidiasis |
66.7% |
| Nausea |
22.2% |
| Depression |
11.1% |
|
| Drug Interaction |
50.0% |
| Sinoatrial Block |
25.0% |
| Ventricular Tachycardia |
12.5% |
| Withdrawal Syndrome |
12.5% |
|
